Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | General Counsel/Secretary | March 15, 2021 | March 17, 2021 |
| Mobia Medical, Inc.MOBI · Entity 5669 | SEE REMARKS | September 11, 2026 | September 15, 2026 |
| Oncternal Therapeutics, Inc.ONCT · Entity 89585 | General Counsel/Secretary | February 14, 2024 | February 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date March 15, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2031-03-15 | Direct | 699,100 |
Reported balance
After 2021-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-15 · Grant · Acquired 699,100 · Balance 699,100 F1: One quarter of the options shall vest on March 15, 2022 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. |
Filing footnotes · ownership attribution and instrument terms
F1: One quarter of the options shall vest on March 15, 2022 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
Mobia Medical, Inc.
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,000 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Purchase · Acquired 2,000 · Balance 5,000 |
Oncternal Therapeutics, Inc.
Report date February 14, 2024 · Filed February 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $9.18 · Expires 2034-02-14 | Direct | 14,200 |
Reported balance
After 2024-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-14 · Grant · Acquired 14,200 · Balance 14,200 F1: 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 20:34 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | PurchaseCommon Stock | 2,000 | $10.30 | $20,600.00 |
DisclosureSEC source: 0001193125-26-391998 · ownership.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:36 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | PurchaseCommon Stock | 3,000 | $15.00 | $45,000.00 |
DisclosureSEC source: 0001628280-26-033808 · wk-form4_1778549795.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:36 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | GrantStock Option · Derivative | 175,760 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001628280-26-033808 · wk-form4_1778549795.xml · derivative · entry 2 Leavitt Chase C. · CIK 0001777467 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,760 Underlying: Common Stock · 175,760 shares Expires 2036-05-07 F1 · derivative.exercise_date: The stock option will vest as to 25% of the underlying shares on May 7, 2027, and will vest thereafter in 36 substantially equal monthly installments. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 18:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 14,200 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001209191-24-003412 · doc4.xml · derivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,200 Underlying: Common Stock · 14,200 shares Expires 2034-02-14 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 16:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Tax withholdingCommon Stock | 11,838 | $0.50 | $5,872.83 |
DisclosureSEC source: 0001209191-24-000971 · doc4.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,758 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 17:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 235,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001209191-23-052023 · doc4.xml · derivative · entry 9 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 235,000 shares Expires 2033-10-02 F8 · derivative.exercise_date: 25% of the Option Shares vested on April 12, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. The option may not be exercised if recipient's employment or service terminates prior to October 2, 2024 other than as a result of a Qualifying Termination. All of the Option Shares vest and become exercisable in the event of a Change in Control. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 17:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 210,000 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-052023 · doc4.xml · derivative · entry 8 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2033-02-21 F7 · derivative.exercise_price: The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised. F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged. F5 · derivative.exercise_date: 25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 17:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 28,750 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-052023 · doc4.xml · derivative · entry 7 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,750 Underlying: Common Stock · 28,750 shares Expires 2032-07-28 F7 · derivative.exercise_price: The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised. F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged. F4 · derivative.exercise_date: 50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan). Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 17:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 55,519 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-052023 · doc4.xml · derivative · entry 6 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,519 Underlying: Common Stock · 55,519 shares Expires 2032-01-20 F7 · derivative.exercise_price: The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised. F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 17:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 65,000 | Not disclosed Strike: $0.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-052023 · doc4.xml · derivative · entry 5 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-04-29 F6 · derivative.exercise_price: The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a "Qualifying Termination"); or (ii) the option is exercised. F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 25% of the shares subject to the option ("Option Shares") vested on April 12, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 17:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Disposition to issuerStock Option · Derivative | 210,000 | Not disclosed Strike: $0.96 | Not disclosed |
DisclosureSEC source: 0001209191-23-052023 · doc4.xml · derivative · entry 4 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 210,000 shares Expires 2033-02-21 F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged. F5 · derivative.exercise_date: 25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 17:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Disposition to issuerStock Option · Derivative | 28,750 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001209191-23-052023 · doc4.xml · derivative · entry 3 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,750 shares Expires 2032-07-28 F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged. F4 · derivative.exercise_date: 50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan). Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 17:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Disposition to issuerStock Option · Derivative | 55,519 | Not disclosed Strike: $1.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052023 · doc4.xml · derivative · entry 2 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,519 shares Expires 2032-01-20 F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 17:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Disposition to issuerStock Option · Derivative | 65,000 | Not disclosed Strike: $6.46 | Not disclosed |
DisclosureSEC source: 0001209191-23-052023 · doc4.xml · derivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2031-04-29 F2 · price: On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 25% of the shares subject to the option ("Option Shares") vested on April 12, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 18:59 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Tax withholdingCommon Stock | 10,305 | $0.36 | $3,709.80 |
DisclosureSEC source: 0001209191-23-041318 · doc4.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,596 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 06:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 10,000 | $0.29 | $2,900.00 |
DisclosureSEC source: 0001209191-23-024264 · doc4.xml · nonDerivative · entry 2 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,901 Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 06:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 15,000 | $0.29 | $4,350.00 |
DisclosureSEC source: 0001209191-23-024264 · doc4.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,901 Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 20:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 210,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001209191-23-012401 · doc4.xml · derivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | Tax withholdingCommon Stock | 6,091 | $1.02 | $6,212.82 |
DisclosureSEC source: 0001209191-23-002031 · doc4.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,901 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 18:22 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 28,750 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-22-043739 · doc4.xml · derivative · entry 2 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,750 Underlying: Common Stock · 28,750 shares Expires 2032-07-28 F2 · derivative.exercise_date: One half of the shares subject to the stock options vest on July 3, 2023 and one half of the shares subject to the stock options vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the shares subject to the stock options vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan). Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 18:22 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantCommon Stock | 43,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043739 · doc4.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,992 F1 · shares: Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on July 3, 2023, and one half of the RSUs vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan). Read SEC document |
| January 28, 2022 Filed Jan 31, 2022 16:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 5,000 | $1.63 | $8,150.00 |
DisclosureSEC source: 0001209191-22-005558 · doc4.xml · nonDerivative · entry 2 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,867 Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 16:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 8,500 | $1.78 | $15,130.00 |
DisclosureSEC source: 0001209191-22-005558 · doc4.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,867 Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 16:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 55,519 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001209191-22-004583 · doc4.xml · derivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,519 Underlying: Common Stock · 55,519 shares Expires 2032-01-20 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in 36 equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 19:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantCommon Stock | 29,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001973 · doc4.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,367 F1 · shares: Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on January 3, 2023, one quarter of the RSUs vest on July 3, 2023, and one quarter of the RSUs vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan). Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 18:00 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | PurchaseCommon Stock | 1,500 | $5.45 | $8,175.00 |
DisclosureSEC source: 0001209191-21-040701 · doc4.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 699,100 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001493152-21-006271 · ownership.xml · derivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 699,100 Underlying: Common Shares · 699,100 shares Expires 2031-03-15 F1 · derivative.exercise_date: One quarter of the options shall vest on March 15, 2022 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 616,700 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001493152-20-004351 · ownership.xml · derivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,700 Underlying: Common Shares · 616,700 shares Expires 2030-03-17 F1 · derivative.exercise_date: One quarter of the options shall vest on March 17, 2021 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 12:42 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares | 5,000 | $1.02 | $5,100.00 |
DisclosureSEC source: 0001209191-19-046031 · doc4.xml · nonDerivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| July 31, 2019 Filed Aug 15, 2019 12:42 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001209191-19-046031 · doc4.xml · derivative · entry 2 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2029-07-30 F1 · derivative.exercise_date: One quarter of the options shall vest on May 20, 2020 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:31 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-19-032073 · doc4.xml · derivative · entry 1 Leavitt Chase C. · CIK 0001777467 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2029-05-19 F1 · derivative.exercise_date: One quarter of the options shall vest on May 20, 2020 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.